Brokers Set Expectations for Daré Bioscience FY2029 Earnings

Daré Bioscience, Inc. (NASDAQ:DARE) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Daré Bioscience in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst D. Tsao forecasts that the biotechnology company will post earnings per share of $15.48 for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share.

Daré Bioscience Stock Down 1.4 %

Shares of NASDAQ DARE opened at $2.89 on Thursday. The stock has a market capitalization of $25.14 million, a P/E ratio of -4.89 and a beta of 1.38. The firm’s 50-day moving average price is $3.03 and its two-hundred day moving average price is $3.28. Daré Bioscience has a 52-week low of $2.67 and a 52-week high of $7.56.

Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.02. The company had revenue of ($0.06) million for the quarter, compared to the consensus estimate of $1.00 million.

Hedge Funds Weigh In On Daré Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of DARE. AMH Equity Ltd increased its holdings in shares of Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 50,000 shares during the period. Jane Street Group LLC purchased a new position in Daré Bioscience in the 4th quarter worth about $52,000. Renaissance Technologies LLC lifted its position in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 4,300 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Daré Bioscience by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares in the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.